Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Refractory or Relapsed Acquired Thrombotic Thrombocytopenic Purpura
jRCT2091220160Completed
- Sponsor
- Saitama Medical University
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in thrombotic thrombocytopenic purpura (TTP), sponsored by Saitama Medical University. Primary endpoint: Response rate at 4 weeks. Started Jan 2014; status: completed.
02
Drugs
rituximab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on jRCT2091220160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220160.